<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256603</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-00117</org_study_id>
    <nct_id>NCT04256603</nct_id>
  </id_info>
  <brief_title>Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI</brief_title>
  <official_title>Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in Spinal Cord Injury (SCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MetroHealth Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuropathic pain is a common complaint in those with spinal cord injury (SCI) that has a
      significant negative effect on quality of life. Efficacy of various treatments, however,
      remains controversial. There is evidence to support that gabapentin and pregabalin have some
      benefit in reducing neuropathic pain. Gabapentin is effective in the management of symptoms
      and concerns related to SCI including motor recovery, spasticity, and mood among others. This
      makes gabapentin an important pharmacologic intervention, which compels providers to define
      treatment guidelines related to its use. One aspect of which should relate to the timing of
      initiation of therapy. The goal of this study is to determine whether timing of initiation of
      treatment with gabapentin will decrease prevalence and intensity of neuropathic pain.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropathic pain</measure>
    <time_frame>Through study completion, an average of 8 weeks</time_frame>
    <description>To determine if the time from injury influences the prevalence of neuropathic pain in acute SCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>Through study completion, an average of 8 weeks</time_frame>
    <description>Overall pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use for pain control</measure>
    <time_frame>Through study completion, an average of 8 weeks</time_frame>
    <description>Use of opiates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>Through study completion, an average of 8 weeks</time_frame>
    <description>Functional Independence Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor</measure>
    <time_frame>Through study completion, an average of 8 weeks</time_frame>
    <description>ASIA impairment scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gabapentin prior to admission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gabapentin during admission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No gabapentin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Timing of gabapentin initiation</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No gabapentin</intervention_name>
    <description>No gabapentin</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of acute spinal cord injury

          2. Admission to acute inpatient rehabilitation

        Exclusion Criteria:

          1. Unable to communicate verbally or by writing, unable to follow basic instructions, or
             unable to answer questions regarding their symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metro Health, Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>C kim</last_name>
    <phone>216 778 4414</phone>
    <email>ckim3@metrohealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>MetroHealth</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Kim</last_name>
      <email>ckim3@metrohealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 1, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MetroHealth Medical Center</investigator_affiliation>
    <investigator_full_name>Chong Kim</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>neuropathic pain</keyword>
  <keyword>spinal cord injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

